TCT 2009 schedule
Here is the page we will use to coordinate the TV events at TCT 2009.
Click on Date for Detailed Schedule
Monday September 21, 2009
1:05 PM
1:05 PM - 1:15 PM
- Event: The Drug-Eluting Stent Summit Part 1: Appropriate Utilization of Current Generation Devices. Session III. DES Safety Considerations
- Room: 104
1:51 PM
1:51 PM - 2:03 PM
- Event: The Drug-Eluting Stent Summit Part 1: Appropriate Utilization of Current Generation Devices. Session III. DES Safety Considerations
- Room: 104
Tuesday September 22, 2009
10:00 AM
10:00 AM - 12:00 PM
- Event: Oral Abstracts- AMI
- Room: 125
12:30 PM
12:30 PM - 1:00 PM
- Event: Interview
- Room: East 264
- Interviewee: Pieter C. Smits
- Confirmed: Yes
- Trial: COMPARE. A Prospective, Randomized Trial of Everolimus-eluting vs. Paclitaxel-Eluting Stents
- Phone number:
1:00 PM
1:00 PM - 1:30 PM
- Event: Interview
- Room: East 264
- Interviewee: Shamir Mehta
- Confirmed: Yes
- Trial: CURRENT-PCI OASIS 7. A Prospective, Randomized, Placebo-Controlled Trial of high vs. Standard Dose Clopidogrel and High vs. Low Dose Aspirin in Patients Undergoing PCI for ACS
- Phone number:
Wednesday September 23, 2009
8:30 AM
8:30 AM - 9:00 AM
- Event: Interview
- Room: East 264
- Interviewee: William Fearon
- Confirmed: Yes
- Trial: FAME: 2-Year Follow-up From a Prospective, Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease
- Phone number:
9:00 AM
9:00 AM - 9:30 AM
- Event: Interview
- Room: East 264
- Interviewee: Lorenz Raber
- Confirmed: Yes
- Trial: SIRTAX-LATE. 5-Year Clinical and Angiographic Follow-up from a Prospective, Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents
- Phone number:
9:30 AM
9:30 AM - 10:00 AM
- Event: Interview
- Room: East 264
- Interviewee: Volker Klauss
- Confirmed: Yes
- Trial: LEADERS. 2-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Edulting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
- Phone number:
10:00 AM
10:00 AM - 10:30 AM
- Event: Interview
- Room: East 264
- Interviewee: Deepak Bhatt
- Confirmed: Yes
- Trial: COGENT. A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel
- Phone number:
10:30 AM
10:30 AM - 11:00 AM
- Event: Interview
- Room: East 264
- Interviewee: David Cohen
- Confirmed: Yes
- Trial: TRITON-TIMI 38 ECONOMIC SUBSTUDY. Cost-Effectiveness of Prasugrel vs. Clopidogrel From a Prospective, Randomized Trial of Patients with ACS Undergoing PCI
- Phone number:
11:00 AM
11:00 AM - 11:30 AM
- Event: Interview
- Room: East 264
- Interviewee: Chris Cannon
- Confirmed: Yes
- Trial: PLATO INVASIVE. A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy
- Phone number:
12:00 PM
12:00 PM - 12:30 PM
- Event: Interview
- Room: East 264
- Interviewee: Robert Byrne
- Confirmed: Yes
- Trial: ISAR-DESIRE 2. A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Restenosis in Sirolimus-Eluting Stents
- Phone number:
12:45 PM
12:45 PM - 12:50 PM
- Event: Open Issues I: Adjunct Pharmacology. Schedule
- Room: 130
1:35 PM
1:35 PM - 1:45 PM
- Event: Open Issues I: Adjunct Pharmacology. Schedule
- Room: 130
4:00 PM
4:00 PM - 4:45 PM
- Event: Main Arena I. Plenary Session #7 Personalized Clinical Decision-Making Case Study: The Ischemia vs. Bleeding Controversy
- Room: Esplanade Ballroom
Thursday September 24, 2009
8:46 AM
8:46 AM - 11:11 AM
- Event: Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 2: Current Choices in Antithrombin Therapy for ACS and PCI
- Room: 135
11:45 PM
11:45 AM - 11:57 AM
- Event: Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 3: Emerging Alternatives for Antiocoagulation for ACS and PCI
- Room: 135
12:09 PM
12:09 PM - 12:24 PM
- Event: Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 3: Emerging Alternatives for Antiocoagulation for ACS and PCI
- Room: 135
5:02 PM
5:02 PM - 5:14 PM
- Event: Balancing Safety and Efficacy of Antithrombotic Therapies for PCI and ACS. Antiplatelet Agents, Bleeding, and Ischemia
- Room: 135
Friday September 25, 2009
2:24 PM
2:24 PM - 2:36 PM
- Event: Top Interventional Trials of the Last Year: Perspectives from the Experts
GPIIb/IIIa Inhibitors in ACS: EARLY ACS
- Room: EBM and Guidelines Theater, Hall D
2:36 PM
2:36 PM - 3:12 PM
- Event: Top Interventional Trials of the Last Year: Perspectives from the Experts
Aspirin and Clopiodgrel in ACS: CURRENT-OASIS 7
- Room: EBM and Guidelines Theater, Hall D
3:00 PM
3:00 PM - 3:12 PM
- Event: Top Interventional Trials of the Last Year: Perspectives from the Experts
Aspirin and Clopiodgrel in ACS: CURRENT-OASIS 7
- Room: EBM and Guidelines Theater, Hall D
3:24 PM
3:24 PM - 3:36 PM
- Event: Top Interventional Trials of the Last Year: Perspectives from the Experts
Ticagrelor in ACS: PLATO
- Room: EBM and Guidelines Theater, Hall D
3:36 PM
3:36 PM - 3:48 PM
- Event: Top Interventional Trials of the Last Year: Perspectives from the Experts
Ticagrelor in ACS: PLATO
- Room: EBM and Guidelines Theater, Hall D